IP Library Granted Patent US 10,428,330
Granted Patent B2
US 10,428,330 · App. 15/990,547 · Granted Oct 1, 2019

Stem-loop compositions and methods for inhibiting factor D

Inventors: Carl Erickson (Corte Madera, CA); Christopher P. Rusconi (Durham, NC); Kevin G. McLure (Oakland, CA); Matthew Levy (Cary, NC); Arijit Bhowmick (Durham, NC)
Assignees: Vitrisa Therapeutics, Inc.; Albert Einstein College of Medicine
C12N15/115A61K31/7088C12N2310/16C12N2310/317C12N2310/321C12N2310/322C12N2310/531
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,428,330
App. No.
15/990,547
Granted
Oct 1, 2019
Kind
B2
Abstract

The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease. In some cases, stem-loop aptamers are provided for the inhibition of Factor D.

Claims (31)

1. An aptamer comprising a nucleic acid sequence that selectively binds to complement factor D (fD) and having a stem-loop secondary structure comprising, in a 5′ to 3′ direction, a first base-paired stem, a first loop, a second base-paired stem, a second loop, and a third loop, wherein said third loop comprises 6 or more nucleotides, non-nucleotidyl spacers, or a combination thereof, and wherein said third loop is adjacent to said first base-paired stem.

2. The aptamer of claim 1 , wherein said first loop has fewer nucleotides than said second loop.

3. The aptamer of claim 1 , wherein said first loop has from 1to 10 nucleotides, non-nucleotidyl spacers, or a combination thereof.

4. The aptamer of claim 1 , wherein said second loop comprises at least 6 nucleotides, non-nucleotidyl spacers, or a combination thereof.

5. The aptamer of claim 1 , wherein said third loop has from 6to 8 nucleotides, non-nucleotidyl spacers, or a combination thereof.

6. The aptamer of claim 1 , wherein said first base-paired stem has from 2 to 10 base pairs.

7. The aptamer of claim 1 , wherein said second base-paired stem has from 2 to 10 base pairs.

8. The aptamer of claim 1 , wherein said third loop comprises at least 4 nucleotides and up to 2 non-nucleotidyl spacers.

9. The aptamer of claim 1 , wherein said third loop comprises at least 6 nucleotides.

10. The aptamer of claim 1 , wherein:

a) said first base-paired stem is adjacent to said first loop;

b) said second base-paired stem is adjacent to said first loop, said second loop, and said third loop; or

c) said first base-paired stem is adjacent to said first loop and said second base-paired stem is adjacent to said first loop, said second loop, and said third loop.

11. The aptamer of claim 1 , wherein said aptamer is an RNA aptamer or a modified RNA aptamer.

12. The aptamer of claim 1 , wherein said aptamer is a DNA aptamer or a modified DNA aptamer.

13. The aptamer of claim 1 , wherein said aptamer comprises one or more modified nucleotides.

14. The aptamer of claim 13 , wherein said one or more modified nucleotides comprises a 2′F-modified nucleotide, a 2′OMe-modified nucleotide, or a combination thereof.

15. The aptamer of claim 1 , wherein said stem-loop structure has exactly two base-paired stems.

16. The aptamer of claim 1 , wherein said aptamer is an RNA aptamer comprising nucleotides having ribose in a β-D-ribofuranose configuration.

17. The aptamer of claim 1 , wherein said aptamer blocks an active site of fD.

18. The aptamer of claim 1 , wherein said aptamer inhibits a function associated with fD.

19. The aptamer of claim 1 , wherein said nucleic acid sequence comprises from 30 to 90 nucleotides, non-nucleotidyl spacers, or a combination thereof.

20. The aptamer of claim 1 , wherein: said aptamer is conjugated to a polyethylene glycol (PEG) molecule.

21. The aptamer of claim 1 , wherein said second loop comprises more than 5 nucleotides, non-nucleotidyl spacers, or a combination thereof.

22. The aptamer of claim 1 , wherein said first base-paired stem has no more than 5 base pairs.

23. The aptamer of claim 1 , wherein said first loop comprises a nucleic acid sequence of 5′-DUG-3′, where D is A, G, or U.

24. The aptamer of claim 1 , wherein said second loop comprises a nucleic acid sequence of 5′-DWWVGCBHWG-3′, where D is A, G, or U; W is A or U; V is A, C, or G; B is C, G, or U; and H is A, C, or U.

25. The aptamer of claim 1 , wherein said second loop comprises a nucleic acid sequence having a U at nucleotide position 2, a U at nucleotide position 3, or both.

26. The aptamer of claim 1 , wherein said third loop comprises a nucleic acid sequence comprising 5′-AAGUKN-3′, where K is G or U; and N is A, G, C, or U.

27. The aptamer of claim 1 , wherein said second base-paired stem comprises a terminal U-G base pair adjacent to said second loop.

28. The aptamer of claim 1 , wherein said second base-paired stem comprises a terminal C-G base pair adjacent to said second loop.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2024
From: 396419 B.C. LTD.; CALW INVESTMENT CO. INC.
To: OAK BAY BIOSCIENCES INC.
Reel/Frame 066421/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2024
From: 396419 B.C. LTD.
To: CALW INVESTMENT CO. INC.
Reel/Frame 066421/0557 →
MERGER AND CHANGE OF NAME Recorded Apr 7, 2022
From: ALBERT EINSTEIN COLLEGE OF MEDICINE; ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 059649/0581 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2020
From: VITRISA THERAPEUTICS, INC.
To: 396419 B.C. LTD.
Reel/Frame 052929/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2019
From: LEVY, MATTHEW; BHOWMICK, ARIJIT
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 049979/0616 →
SECURITY INTEREST Recorded Apr 17, 2019
From: VITRISA THERAPEUTICS, INC.
To: SILICON VALLEY BANK
Reel/Frame 048907/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2018
From: ERICKSON, CARL; RUSCONI, CHRISTOPHER P.; MCLURE, KEVIN G.
To: VITRISA THERAPEUTICS, INC.
Reel/Frame 047345/0302 →
Continuity (4)
Continuation PCTUS2018014573 · Jan 19, 2018
Provisional Application 62536387 · Jul 24, 2017
Provisional Application 62448872 · Jan 20, 2017
Related Publication 20190032056A1 · Jan 31, 2019